Olema Pharmaceuticals Shares Owned By Insiders vs. Total Debt
| OLMA Stock | USD 8.89 0.75 7.78% |
For Olema Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Olema Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Olema Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Olema Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Olema Pharmaceuticals over time as well as its relative position and ranking within its peers.
Olema |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Olema Pharmaceuticals Total Debt vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Olema Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Olema Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Olema Pharmaceuticals is rated below average in shares owned by insiders category among its peers. It is rated below average in total debt category among its peers making up about 658,583 of Total Debt per Shares Owned By Insiders. As of December 11, 2024, Total Debt To Capitalization is expected to decline to 0. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Olema Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Olema Total Debt vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Olema Pharmaceuticals |
| = | 3.67 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Olema Pharmaceuticals |
| = | 2.42 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Olema Total Debt vs Competition
Olema Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 640.63 Million. Olema Pharmaceuticals adds roughly 2.42 Million in total debt claiming only tiny portion of equities under Health Care industry.
Olema Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Olema Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Olema Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Olema Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Olema Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 347 K | 364.4 K | |
| Net Interest Income | 5.7 M | 6 M | |
| Interest Income | 5.7 M | 6 M | |
| Operating Income | -105 M | -99.7 M | |
| Net Loss | -96.1 M | -91.3 M | |
| Income Before Tax | -96.7 M | -91.8 M | |
| Total Other Income Expense Net | 8.3 M | 8.7 M | |
| Net Loss | -94.3 M | -89.6 M | |
| Net Loss | -96.7 M | -91.8 M | |
| Income Tax Expense | -2 M | -1.9 M | |
| Non Operating Income Net Other | 2.5 M | 1.4 M | |
| Change To Netincome | 21.7 M | 22.7 M | |
| Net Loss | (2.14) | (2.24) | |
| Income Quality | 0.87 | 0.91 | |
| Net Income Per E B T | 1.13 | 1.10 |
Olema Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Olema Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Olema Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Olema Pharmaceuticals' important profitability drivers and their relationship over time.
Use Olema Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Olema Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Olema Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Olema Pharmaceuticals Pair Trading
Olema Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Olema Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Olema Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Olema Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Olema Pharmaceuticals to buy it.
The correlation of Olema Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Olema Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Olema Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Olema Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Olema Pharmaceuticals position
In addition to having Olema Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1286 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Olema Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Olema Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Olema Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.